STOCK TITAN

CareDx to Report Third Quarter 2020 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it will release financial results for the third quarter 2020 after the close of trading on Thursday, October 29, 2020. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.

Individuals interested in listening to the conference call may do so by dialing 877-705-6003 for domestic callers or 201-493-6725 for international callers. Please reference Conference ID: 13711048. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: www.CareDx.com.

A replay of the call will be available beginning October 29, 2020, at 4:30pm PT/7:30pm ET through 8:59pm PT/11:59pm ET on November 12, 2020. To access the replay, dial-in 1-844-512-2921 or 1-412-317-6671 and reference Conference ID: 13711048. The webcast will also be available on CareDx’s website for one year following the completion of the call.

About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CONTACTS:
Greg Chodaczek
347-620-7010
investor@caredx.com

CareDx, Inc.

NASDAQ:CDNA

CDNA Rankings

CDNA Latest News

CDNA Stock Data

575.21M
50.37M
3.75%
100.35%
10%
Medical Laboratories
Health Care and Social Assistance
Link
United States of America
BRISBANE

About CDNA

caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos